CHEST Clinical Trials Opportunities

Sponsoring company: Boehringer Ingelheim Pharmaceuticals, Inc.
Disease state: bronchiectasis, cystic fibrosis bronchiectasis, non-cystic fibrosis bronchiectasis

A phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5mg administered once daily for up to 76 weeks in patients with bronchiectasis.

CLINICALTRIALS.GOV LINK »

STUDY LINK »

Sponsoring company: Avalyn Pharma
Disease state: progressive pulmonary fibrosis

The MIST PPF Study is a global phase 2b clinical research study to evaluate the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). This randomized, double-blind, placebo-controlled study is expected to enroll approximately 300 individuals with PPF across North America, South America, Europe, and Asia-Pacific.

The primary endpoint of the study is change from baseline in forced vital capacity (FVC) at week 52. Secondary endpoints include quality of life measurements, time to disease progression, and change in lung fibrosis score based on high-resolution computed tomography (HRCT). Additional exploratory outcomes will also be evaluated.

This clinical research study is for adults age 18 and older with PPF, who show worsening symptoms and/or decline in lung function. Patients can be on background immunosuppressants or oral nintedanib.

CLINICALTRIALS.GOV LINK »

STUDY LINK »

Sponsoring company: GSK
Disease state: COPD

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with type 2 inflammation.

CLINICALTRIALS.GOV LINK »

Sponsoring company: GSK
Disease state: refractory chronic cough

This is a randomized, double-blind, placebo-controlled, parallel-arm, phase 3 study of BLU-5937 in participants with refractory chronic cough (RCC).

CLINICALTRIALS.GOV LINK »

Sponsoring company: Bristol Myers Squibb
Disease state: pulmonary fibrosis

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with progressive pulmonary fibrosis.

CLINICALTRIALS.GOV LINK »

STUDY LINK »